Log in

NASDAQ:JAZZJazz Pharmaceuticals Stock Price, Forecast & News

$109.59
-1.26 (-1.14 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$109.12
Now: $109.59
$110.99
50-Day Range
$98.76
MA: $109.37
$115.72
52-Week Range
$86.88
Now: $109.59
$154.24
Volume426,070 shs
Average Volume618,022 shs
Market Capitalization$6.06 billion
P/E Ratio22.78
Dividend YieldN/A
Beta1.22
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson's disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.
Read More
Jazz Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.25 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone011-353-1634-7800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$22.23 per share
Book Value$54.99 per share

Profitability

Net Income$523.37 million

Miscellaneous

Employees1,620
Market Cap$6.06 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

How has Jazz Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JAZZ stock has increased by 1.4% and is now trading at $109.59. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Jazz Pharmaceuticals?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jazz Pharmaceuticals.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Jazz Pharmaceuticals.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its quarterly earnings results on Tuesday, May, 5th. The specialty pharmaceutical company reported $0.45 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.24. The specialty pharmaceutical company earned $534.73 million during the quarter, compared to analysts' expectations of $544.55 million. Jazz Pharmaceuticals had a net margin of 12.81% and a return on equity of 21.66%. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $3.67 EPS. View Jazz Pharmaceuticals' earnings history.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided EPS guidance of 11.25-12.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.31. The company issued revenue guidance of $2.12-2.26 billion, compared to the consensus revenue estimate of $2.3 billion.

What price target have analysts set for JAZZ?

19 analysts have issued 1-year price objectives for Jazz Pharmaceuticals' shares. Their forecasts range from $109.00 to $200.00. On average, they expect Jazz Pharmaceuticals' stock price to reach $156.22 in the next year. This suggests a possible upside of 42.6% from the stock's current price. View analysts' price targets for Jazz Pharmaceuticals.

What are Wall Street analysts saying about Jazz Pharmaceuticals stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Jazz’s key drug, Xyrem, continues to witness improved volume trends in 2019 on the back of awareness efforts. The label expansion of Xyrem in pediatric patients has improved the top line further. Management expects Xyrem's volume growth to continue in the second half. Sunosi's launch in July 2019 complements the sleep franchise and its successful commercialization may offset a decline in Xyrem’s sales following patent expiry in 2023. Jazz’s leukemia drug, Vyxeos, has also witnessed strong growth so far in 2019. Its launch in Europe boosted sales in 2019. However, Jazz has been facing supply crunch for its leukemia drug, Erwinaze, owing to constrained manufacturing capacity, which is likely to continue in second half. Defitelio sales also vary every quarter." (9/13/2019)
  • 2. HC Wainwright analysts commented, "Our $147 12-month target (from $153) is based on a DCF, which reflects a strong 15% 2019-22 cash- flow CAGR, a 10% WACC discount rate, and negative 3.5% terminal growth after 2022 given conservatively assumed modest Xyrem franchise headwinds partially offset by other products’ continued growth." (8/8/2019)

Has Jazz Pharmaceuticals been receiving favorable news coverage?

News articles about JAZZ stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Jazz Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutJazz Pharmaceuticals.

Are investors shorting Jazz Pharmaceuticals?

Jazz Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 2,790,000 shares, a drop of 5.4% from the April 30th total of 2,950,000 shares. Based on an average trading volume of 693,300 shares, the short-interest ratio is currently 4.0 days. Currently, 5.2% of the shares of the company are short sold. View Jazz Pharmaceuticals' Current Options Chain.

Who are some of Jazz Pharmaceuticals' key competitors?

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Visa (V), Bank of America (BAC) and Biogen (BIIB).

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:
  • Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Matthew P. Young, Exec. VP & CFO (Age 50)
  • Mr. Daniel N. Swisher Jr., Pres & COO (Age 56)
  • Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 56)
  • Mr. Paul Treacy, Sr. VP of Technical Operations (Age 58)

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.15%), AQR Capital Management LLC (4.25%), JPMorgan Chase & Co. (3.19%), Nuveen Asset Management LLC (2.96%), State Street Corp (2.72%) and Janus Henderson Group PLC (1.49%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul Treacy, Rick E Winningham, Seamus Mulligan and Suzanne Sawochka Hooper. View institutional ownership trends for Jazz Pharmaceuticals.

Which major investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, BlackRock Inc., Assenagon Asset Management S.A., JPMorgan Chase & Co., Nuveen Asset Management LLC, KBC Group NV, Wellington Management Group LLP, and AJO LP. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Michael Patrick Miller, Patricia Carr, and Paul Treacy. View insider buying and selling activity for Jazz Pharmaceuticals.

Which major investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Sarissa Capital Management LP, APG Asset Management N.V., Janus Henderson Group PLC, PNC Financial Services Group Inc., First Trust Advisors LP, Robeco Institutional Asset Management B.V., and Systematic Financial Management LP. View insider buying and selling activity for Jazz Pharmaceuticals.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $109.59.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $6.06 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis. Jazz Pharmaceuticals employs 1,620 workers across the globe.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at investor.jazzpharma.com.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.